GlassScriptPhysician profile
Macy Catalano
NPI 1215492475
$3,509.83
in general payments reported to CMS, 2019-2025
34 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $686 · 2022: $470 · 2023: $891 · 2024: $1,224 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,354.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $861.21 | 2024-2025 | |
| Abbvie INC. | $593.45 | 2021-2024 | |
| Glaxosmithkline, LLC. | $421.20 | 2021-2024 | Trelegy Ellipta |
| Amgen INC. | $253.85 | 2022-2025 | Otezla, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.10 | 2021-2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $147.80 | 2021-2023 | Jardiance, Mounjaro, Emgality |
| Takeda Pharmaceuticals U.S.A., INC. | $131.55 | 2021-2024 | Trintellix |
| Novo Nordisk INC | $127.99 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Antares Pharma, INC. | $85.34 | 2022-2023 | Nocdurna, Xyosted, Tlando |
| Noven Therapeutics, LLC | $72.76 | 2023-2024 | Xelstrym, Secuado |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.56 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $51.27 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $48.95 | 2023-2024 | Rexulti |
| Axsome Therapeutics, INC. | $44.80 | 2024 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $42.03 | 2022-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $36.55 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $32.78 | 2021 | Xyosted |
| Sanofi-Aventis U.S. LLC | $30.13 | 2021 | |
| Revance Therapeutics, INC. | $28.27 | 2024 | Daxxify |
| Halozyme INC | $24.74 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.62 | 2024 | Caplyta |
| Eisai INC. | $24.09 | 2021 | |
| Ironshore Pharmaceuticals INC. | $22.43 | 2023 | Jornay Pm |
| Renalytix Ai, INC. | $22.28 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Xeris Pharmaceuticals, INC. | $21.27 | 2023 | Gvoke Hypopen |
| Tris Pharma INC | $20.96 | 2024 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $17.93 | 2021 | |
| Pfizer INC. | $17.74 | 2023 | |
| Acerus Pharmaceuticals Corporation | $17.68 | 2021 | |
| Boston Scientific Corporation | $17.29 | 2023 | Watchman Flx |
| Avion Pharmaceuticals | $15.16 | 2023 | Balcoltra |
| Bausch Health US, LLC | $15.13 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $13.83 | 2024 | Kristalose |
| Idorsia Pharmaceuticals US INC | $13.09 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Macy Catalano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.